Publications by authors named "V Chylak"

8 Publications

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

Br J Cancer 1998 Dec;78(11):1479-87

The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063202PMC
http://dx.doi.org/10.1038/bjc.1998.710DOI Listing
December 1998

[Uterine sarcoma--diagnostic and therapeutic problems].

Jugosl Ginekol Perinatol 1990 May-Aug;30(3-4):109-10

Sredisnji institut za tumore i sline bolesti, Zagreb.

A retrospective analysis dealt with 28 cases of uterine sarcoma treated in a ten-year period (1975-1984). The most common histological type was leiomyosarcoma. Thirteen patients underwent surgery alone, a combination of surgery and irradiation was performed in 9 patients, surgery + irradiation + chemotherapy in 2 patients, and surgery + chemotherapy in 2 patients. Sixteen patients are alive and well during a follow-up of 5 years.
View Article and Find Full Text PDF

Download full-text PDF

Source
February 1991

Activity of epirubicin in combination chemotherapy of advanced ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study.

Oncology 1987 ;44(2):69-72

The therapeutic efficacy of the combination of cyclophosphamide + epirubicin + cisplatin was evaluated in 107 previously treated or untreated patients with advanced ovarian cancer. The overall response rate was 58.8%, complete remission 36.4% (mean duration-7.62 months) and partial remission 22.4% (mean duration-6.74 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 109 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to CAP regimen is demonstrated.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1159/000226447DOI Listing
June 1987
-->